Be Aware of New Warnings for Janus Kinase Inhibitors (Xeljanz, etc)
October 2019
Patients may present to your emergency department with adverse effects from Janus kinase (JAK) inhibitors...tofacitinib (Xeljanz), etc.
These oral meds are used for autoimmune diseases, such as rheumatoid arthritis and ulcerative colitis.
Now there's a boxed warning about an increased risk of thromboembolism with tofacitinib. The JAK inhibitors baricitinib (Olumiant) and upadacitinib (Rinvoq) also carry this warning.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote